Literature DB >> 17492768

PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.

Robert D Loberg1, Kwanchanit Tantivejkul, Matthew Craig, Chris K Neeley, Kenneth J Pienta.   

Abstract

Patients with advanced prostate cancer often exhibit increased activation of the coagulation system. The key activator of the coagulation cascade is the serine protease thrombin which is capable of eliciting numerous cellular responses. We previously reported that the thrombin receptor PAR1 is overexpressed in prostate cancer. To investigate further the role of PAR1 in prostate cancer metastasis, we examined the effects of thrombin activation on cell adhesion and motility in PC-3 prostate cancer cells. Activation of PAR1-induced dynamic cytoskeletal reorganization and reduced PC-3 binding to collagen I, collagen IV, and laminin (P < 0.01) but not fibronectin. Expression of the cell surface integrin receptors did not change as assessed by flow cytometry. Immunofluorescence microscopy revealed that PAR1 stimulation caused reorganization of the focal adhesions, suggesting that PAR1 activation in PC-3 cells may be modulating cell adhesion through integrin function but not expression. Furthermore, RhoA was activated upon stimulation with thrombin with subsequent cell contraction, decreased cell adhesion, and induced migration towards monocyte chemoattractant protein 1 (MCP-1; CCL2). Thus, it appears that thrombin stimulation plays a role in prostate cancer metastasis by decreasing cell adhesion to the extracellular matrix and positioning the cell in a "ready state" for migration in response to a chemotactic signal. Further exploration is needed to determine whether PAR1 activation affects other signaling pathways involved in prostate cancer. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492768     DOI: 10.1002/jcb.21252

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  19 in total

1.  Definition of molecular determinants of prostate cancer cell bone extravasation.

Authors:  Steven R Barthel; Danielle L Hays; Erika M Yazawa; Matthew Opperman; Kempland C Walley; Leonardo Nimrichter; Monica M Burdick; Bryan M Gillard; Michael T Moser; Klaus Pantel; Barbara A Foster; Kenneth J Pienta; Charles J Dimitroff
Journal:  Cancer Res       Date:  2012-11-13       Impact factor: 12.701

Review 2.  Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

Authors:  Jian Zhang; Yi Lu; Kenneth J Pienta
Journal:  J Natl Cancer Inst       Date:  2010-03-16       Impact factor: 13.506

3.  Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4.

Authors:  Jianghua Wang; Yi Cai; Long-Jiang Shao; Javed Siddiqui; Nallasivam Palanisamy; Rile Li; Chengxi Ren; Gustavo Ayala; Michael Ittmann
Journal:  Cancer Res       Date:  2010-12-17       Impact factor: 12.701

4.  Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells.

Authors:  Kasem Nithipatikom; Ana Doris Gomez-Granados; Alan T Tang; Adam W Pfeiffer; Carol L Williams; William B Campbell
Journal:  Endocrinology       Date:  2011-11-15       Impact factor: 4.736

5.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Authors:  Xin Li; Robert Loberg; Jinhui Liao; Chi Ying; Linda A Snyder; Kenneth J Pienta; Laurie K McCauley
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 6.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

7.  KiSS1 suppresses TNFalpha-induced breast cancer cell invasion via an inhibition of RhoA-mediated NF-kappaB activation.

Authors:  Sung-Gook Cho; Dali Li; Lewis J Stafford; Jian Luo; Melissa Rodriguez-Villanueva; Ying Wang; Mingyao Liu
Journal:  J Cell Biochem       Date:  2009-08-15       Impact factor: 4.429

8.  CCL2 in the Tumor Microenvironment.

Authors:  Tracy O'Connor; Mathias Heikenwalder
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms.

Authors:  Wei Bin Fang; Iman Jokar; An Zou; Diana Lambert; Prasanthi Dendukuri; Nikki Cheng
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

10.  Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity.

Authors:  Jeffery G Herman; Henry L Stadelman; Charles E Roselli
Journal:  Int J Oncol       Date:  2009-05       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.